User login
Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.
Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.
Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.
Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027
Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.
Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.
Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.
Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027
Key clinical point: Atopic dermatitis (AD) had a detrimental impact on the families of pediatric patients, with not only severe AD but even mild AD having a substantial impact on family life.
Major finding: There was a substantial impact of AD on families across geographic regions, as assessed by Dermatitis Family Impact (DFI) score, which increased with the severity of AD (mild: 3.3-11.3, moderate: 6.9-17.1, and severe: 11-20.3). A DFI score of >9.6 was reported for 37.2%, 70.7%, and 78.0% of patients with mild, moderate, and severe AD, respectively.
Study details: Findings are from the cross-sectional, web-based survey including 7465 pairs of pediatric patients with AD and their parents/caregivers.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Five authors declared being current or former employees or stockholders of Sanofi or Regeneron Pharmaceuticals, and some others declared ties with various sources.
Source: Barbarot S et al. The family impact of atopic dermatitis in the pediatric population: Results from an international cross-sectional study. J Pediatr. 2022 (Apr 28). Doi: 10.1016/j.jpeds.2022.04.027